ARTICLE: Why Absorica LD?

May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | 3s | Copyright © May 2021

Published online April 23, 2021

Leon H. Kircik MD

There are many patients with severe nodulocystic acne or potentially scarring acne for whom isotretinoin therapy should be implemented as early as possible in the disease course. Early intervention can reduce the risk for scarring, diminish patient discomfort, and minimize the psychosocial impact of the disease. For those patients for whom isotretinoin is an appropriate treatment option, Absorica LD, which has no legally substitutable product, may offer distinct advantages over other formulations of the drug.

Leon H. Kircik MD
Icahn School of Medicine at Mount Sinai, New York, NY
Indiana University Medical Center, Indianapolis, IN
Physicians Skin Care, PLLC, Louisville, KY
DermResearch, PLLC, Louisville, KY
Skin Sciences, PLLC, Louisville, KY

Leon H. Kircik MD has received compensation from JDD for his editorial support and serves as either a speaker, investigator, consultant, or an advisory board member for Sun Pharma.

1. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. Sep 2008;27(3):197-206.
2. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361-372.
3. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
4. Madan S, Kumar S, Segal J. Comparative pharmacokinetic profiles of a novel low-dose micronized-isotretinoin 32 mg formulation and lidose-isotretinoin 40 mg in fed and fasted conditions: Two open-label, randomized, crossover studies in healthy adult participants. Acta Derm Venereol. Feb 2020;100(4):adv00049.